Vertical Pharmaceuticals, Inc. Announces New Co-promote Agreement for Zonatuss™ (Benzonatate Capsules, USP)
SAYREVILLE, N.J.--(BUSINESS WIRE)--Vertical Pharmaceuticals, Inc. today announced that Vertical and Poly Pharmaceuticals, Inc. have entered into a co-promotion agreement for Vertical’s FDA-approved cough suppressant Zonatuss™ (benzonatate capsules, USP).
Under the terms of the agreement, Poly Pharmaceuticals sales specialists that focus on the cold and respiratory market will promote Zonatuss™ to their current customers starting in October 2013.
“We are excited about the partnership with Poly Pharmaceuticals, it allows us to expand our promotional reach to new customers with Poly’s experienced sales team,” said Greg Voyles, Vertical’s Chief Operating Officer. “With the addition of Poly’s sales force we can give customers an opportunity to offer their patients an important option in this therapeutic category.”
“We look forward to working with our partners at Vertical to introduce Zonatuss to our customers,” said Chase Williams, Chief Executive Officer of Poly Pharmaceuticals. “We are committed to providing valuable therapeutic options to customers and patients and feel Zonatuss is consistent with the Poly Pharmaceuticals mission.”
About Zonatuss™ (benzonatate capsules, USP)
Zonatuss™ (benzonatate capsules, USP) is indicated for the symptomatic relief of cough. Each capsule, for oral administration, contains 150mg of benzonatate. It is a non-narcotic anti-tussive, and is decongestant and antihistamine free. Zonatuss™ suppresses the cough reflex at its source and begins working in 15 – 20 minutes.
Zonatuss™ acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs and pleura, thereby reducing the cough reflex.
Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.
Benzonatate has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
Isolated instances of psychiatric effects have been reported in patients taking benzonatate in combination with other prescribed drugs.
Zonatuss™ contraindications: hypersensitivity to benzonatate or related compounds.
For complete prescribing information and important safety information please visit www.verticalpharma.com/Zonatuss.
About Vertical Pharmaceuticals, Inc.
Vertical Pharmaceuticals, Inc. is a privately owned pharmaceutical company founded in 2003 with a clear focus in mind – to develop, market, and acquire products offering therapeutic benefits for patients and healthcare providers. The Company specializes in Women’s Health and Pain Management. Our prescription medications are marketed by our dedicated nationwide sales force throughout the US market. Achieving patient satisfaction is fundamental to our business. We are committed to marketing trusted medicines, making a difference in people’s lives with products of the highest quality.
For more information, please visit the company’s website at www.verticalpharma.com.
About Poly Pharmaceuticals, Inc.
Poly Pharmaceuticals, Inc. is a privately held company founded in 1980 by a group of pharmacists focused on developing and marketing branded, generic, and OTC pharmaceutical products. This remains our focus today. Poly markets a broad range of health care products for conditions such as cough, cold, allergy, sinusitis, pain relief, and urological health.
Poly Pharmaceuticals continues to bring new products to market each year through strategic business alliances, acquisitions, product development, and licensing. Poly is dedicated to developing a portfolio of innovative, safe, and cost-effective medications for patients and caregivers.